Apellis Pharmaceuticals Inc. (APLS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Contrasting side by side

We are comparing Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. 18 0.00 N/A -2.77 0.00
Brainstorm Cell Therapeutics Inc. 4 0.00 N/A -0.69 0.00

Table 1 demonstrates Apellis Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows Apellis Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -77.1% -60.8%
Brainstorm Cell Therapeutics Inc. 0.00% -176% -100.7%


Apellis Pharmaceuticals Inc.’s Current Ratio is 15.2 while its Quick Ratio is 15.2. On the competitive side is, Brainstorm Cell Therapeutics Inc. which has a 1.7 Current Ratio and a 1.7 Quick Ratio. Apellis Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Apellis Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
Brainstorm Cell Therapeutics Inc. 0 0 1 3.00

Apellis Pharmaceuticals Inc. has a 92.31% upside potential and a consensus price target of $45. Competitively Brainstorm Cell Therapeutics Inc. has a consensus price target of $9, with potential upside of 130.18%. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than Apellis Pharmaceuticals Inc. as far as analyst belief.

Insider and Institutional Ownership

Apellis Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc. has shares held by institutional investors as follows: 53.8% and 11.9%. Insiders held roughly 0.1% of Apellis Pharmaceuticals Inc.’s shares. On the other hand, insiders held about 1.4% of Brainstorm Cell Therapeutics Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 2.44% -0.47% 34.54% 27.47% -23.33% 43.52%
Brainstorm Cell Therapeutics Inc. -1.49% 1.79% 2.58% 27.65% 5.03% 11.83%

For the past year Apellis Pharmaceuticals Inc.’s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.


Apellis Pharmaceuticals Inc. beats on 5 of the 7 factors Brainstorm Cell Therapeutics Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.